Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03145259 · ClinicalTrials.gov registry record · Early Phase 1

Evaluation of Bioavailability of Diclofenac Dermal Products

A Early Phase 1 study, sponsored by University of Maryland, Baltimore.

Completed
Registry status
Early Phase 1
Development phase
12
Enrollment target

NCT03145259 is a Early Phase 1 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 12 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03145259, a Early Phase 1 study, has completed, sponsored by University of Maryland, Baltimore.

COMPLETED
Registry status
Early Phase 1
Development phase
12 participants
Enrollment target

Study Summary

The study will utilize already FDA-approved marketed diclofenac products in healthy adults to generate data for establishing rate of drug delivery comparisons between diclofenac epolamine patches and diclofenac sodium solution in healthy adults and to determine skin concentrations.

Interventions

  • DRUG Diclofenac Epolamine Patch
  • DRUG diclofenac sodium solution

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2017-04-19
Est. Completion 2020-05-15
Phase Early Phase 1

Sponsor

University of Maryland, Baltimore

560 total trials

What the Registry Record Tells You About NCT03145259

The ClinicalTrials.gov registry entry for NCT03145259 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Diclofenac Epolamine Patch is the first listed.

NCT03145259 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03145259 about?

NCT03145259 is a clinical study titled "Evaluation of Bioavailability of Diclofenac Dermal Products". The study will utilize already FDA-approved marketed diclofenac products in healthy adults to generate data for establishing rate of drug delivery comparisons between diclofenac epolamine patches and diclofenac sodium solution in healthy adults and to determine skin concentrations.

What is the current status of trial NCT03145259?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2017-04-19. Estimated completion is 2020-05-15.

What interventions are being tested in trial NCT03145259?

The interventions under investigation include: Diclofenac Epolamine Patch (DRUG), diclofenac sodium solution (DRUG).

Who is sponsoring clinical trial NCT03145259?

This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.